Literature DB >> 33719070

Paraneoplastic pemphigus: Revised diagnostic criteria based on literature analysis.

Steven A Svoboda1, Simo Huang2, Xinyang Liu3, Sylvia Hsu2, Kiran Motaparthi4.   

Abstract

BACKGROUND: Paraneoplastic pemphigus (PNP) is a rare autoimmune bullous disease classically associated with an underlying neoplasm. The heterogeneous clinical and histopathologic features of the disease make diagnosis challenging for clinicians. There are no formally accepted diagnostic criteria, and newer techniques for identifying antibodies directed against plakin proteins have largely replaced immunoprecipitation, the historic gold standard.
METHODS: An analysis of 265 published cases of PNP was performed. The clinical, histopathologic, and immunologic features of PNP were assessed.
RESULTS: Based on this review, we modified previous diagnostic criteria to capture 89.4% of PNP cases compared to 71.2% of cases captured by the most commonly referenced criteria devised by Camisa and Helm (p-value < 0.01, z-test; 95% CI [10.2, 33.6]).
CONCLUSION: These revised diagnostic criteria address the variable clinical, histopathologic, and biochemical features of PNP, allowing physicians to have greater confidence in diagnosis of this rare and often fatal disease. The revised criteria include three major criteria and two minor criteria, whereby meeting either all three major criteria or two major and both minor criteria would fulfill a diagnosis of paraneoplastic pemphigus. The major criteria include (a) mucous membrane lesions with or without cutaneous involvement, (b) concomitant internal neoplasm, and (b) serologic evidence of anti-plakin antibodies. The minor criteria include (a) acantholysis and/or lichenoid interface dermatitis on histopathology and (b) direct immunofluorescence staining showing intercellular and/or basement membrane staining.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  autoimmune bullous; diagnostic criteria; paraneoplastic autoimmune multiorgan syndrome; paraneoplastic dermatoses; paraneoplastic pemphigus

Mesh:

Substances:

Year:  2021        PMID: 33719070     DOI: 10.1111/cup.14004

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  4 in total

1.  Vesiculobullous Diseases.

Authors:  Simo Huang; Sylvia Hsu; Kiran Motaparthi
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

2.  Antibody-Negative Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS) in a Patient with Follicular Lymphoma Accompanied by an Excess of Peripheral Blood CD8+ Lymphocytes.

Authors:  Thilo Gambichler; Yi-Pei Lee; Ilske Oschlies; Christina H Scheel; Wolfram Klapper; Nico Nowack; Martin Doerler; Markus Stücker; Nasreddin Abolmaali; Laura Susok
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

3.  Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus.

Authors:  Johanna Freund; Franz Trautinger; Gerhard Kopetzky; Knut Prillinger
Journal:  JAAD Case Rep       Date:  2022-07-16

4.  Indirect immunofluorescence on rat bladder epithelium in patients with pemphigus vulgaris with an extended follow-up.

Authors:  Mahsa Samadi; Anahita Najafi; Amir Naziriyan; Roja Toosi; Atefeh Faramarzi; Kamran Balighi; Pedram Noormohammadpour; Hamidreza Mahmoudi; Maryam Daneshpazhooh
Journal:  Skin Health Dis       Date:  2022-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.